A Study to Evaluate Role of Inhaled Amikacin to Prevent Ventilator Associated Pneumonia in Patients With Cirrhosis

Recruiting now · Phase 4 · Has a placebo group

Conditions studied: Hepatic Encephalopathy, Cirrhosis, Ventilator Associated Pneumonia (VAP)

In brief

The recent AMIKINHAL trial found that prophylactic inhaled amikacin was effective in lowering the incidence of ventilator-associated pneumonia in ICU patients. Since aspiration is a common complication of cirrhosis patients with HE (7 out of 10 patients develop some type of HE) who are hospitalized to the liver ICU also have an elevated risk of Ventilator associated pneumonia. Despite supportive care and appropriate antimicrobial therapy pneumonia is linked to greater mortality in cirrhosis. This poses a significant challenge to physicians. Due to the lack of randomized controlled trials (RCTs) on the prophylaxis of VAP in cirrhosis patients with HE, conducting this study is necessary to evaluate the efficacy of inhaled amikacin. The study results may provide evidence -based guidance for therapy in this patient population.

Key facts

Study ID

NCT06808074

Run by

Asian Institute of Gastroenterology, India

People needed

162

Starts

2025-02-12

Expected to finish

2026-05-01

Last updated by the study team

2025-04-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients admitted to the liver ICU with hepatic encephalopathy (Grade 2 or higher), requiring intubation for at least 48 hours, without pneumonia.
• Patient is aged ≥18 years.
• Written informed consent of the patient or a proxy.

You may not qualify if…

• Suspected or confirmed Pneumonia at the day of inclusion.
• Patients with Chronic kidney disease on maintenance hemodialysis
• Stage 2 or 3 Kidney Disease Improving Global Outcome (KDIGO) classification AKI the day of inclusion. Patients undergoing renal replacement therapy or for whom decision has been made to initiate renal replacement therapy can be included whatever the KDIGO stage
• Pregnancy or breast-feeding.
• Clinical indication for systemic aminoglycoside therapy the day of inclusion: as deemed necessary by the clinician in charge.
• Patients known to be allergic to aminoglycosides.
• Patients who received intravenous Amikacin before 7 days of inclusion in this study.

Where it is running

• AIG Hospitals — Hyderabad, Telangana, India (enrolling)
• Asian Institute of Gastroenterology — Hyderabad, Telangana, India (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.